Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry

Nancy L. Bartlett, Mitchell R. Smith, Tanya Siddiqi, Ranjana H. Advani, Owen A. O’Connor, Jeff P. Sharman, Tatyana Feldman, Kerry J. Savage, Andrei R. Shustov, Catherine S. Diefenbach, Yasuhiro Oki, Maria Corinna Palanca-Wessels, Mayur Uttarwar, Martha Li, Jing Yang, Eric D. Jacobsen

Research output: Contribution to journalArticlepeer-review

33 Scopus citations

Abstract

This phase 2 study evaluated brentuximab vedotin monotherapy in CD30-expressing DLBCL; after several patients with little to no CD30 achieved a complete remission (CR), the study evaluated treatment of DLBCL with undetectable CD30 (CD30u) by local visual immunohistochemistry (vIHC). Sixteen of 52 CD30u DLBCL patients (31%) had an objective response (6 CRs [12%]). Median progression-free survival (PFS) was 1.4 months (range, 0.4–15.6) and median overall survival (OS) was 7.5 months (range, 0.7–18.6+). Subsequent CD30 expression quantitated by computer-assisted digital image analysis (cIHC) showed that 11 of 16 CD30u DLBCL responders had ≥1% CD30. Correlative analyses of CD30u and CD30-expressing DLBCL combined demonstrated that ≥1% CD30 expression by cIHC resulted in a trend toward a higher response rate and significantly longer median PFS and OS. A minimum CD30 expression threshold appears to be required for antitumor activity in DLBCL; however, other factors also likely contribute to activity. (NCT01421667).

Original languageEnglish
Pages (from-to)1607-1616
Number of pages10
JournalLeukemia and Lymphoma
Volume58
Issue number7
DOIs
StatePublished - Jul 3 2017

Keywords

  • DLBCL
  • antibody-based immunotherapy
  • antibody-drug conjugate
  • immunotherapy
  • lymphoma

Fingerprint

Dive into the research topics of 'Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry'. Together they form a unique fingerprint.

Cite this